'The most exciting company in Australia': The ASX stock up 179% in 6 months

This outfit remains a bargain despite almost tripling its share price since June, say experts.

| More on:
A doctor sits with a patient and uses a pen to point to certain parts of her mammogram scan

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If an ASX biotech stock has almost tripled in 6 months but the valuation still remains "cheap", then you would be careless to not at least consider adding it to your portfolio.

According to Frazis Capital portfolio manager Michael Frazis, Sydney company Clarity Pharmaceuticals Ltd (ASX: CU6) has been "on a bit of a tear".

"This is the most exciting company I've come across in Australia lately," he said in a memo to clients.

"Clarity has been steadily releasing data from patients treated with their copper therapies with late stage prostate cancer."

That data has apparently been favourable, causing the share price to rocket 179% from its 52-week low in late June.

Biotechs snapped up for billions with early data

Frazis said that mergers and acquisitions activity in the global biotechnology industry has been "intense".

And those transactions provide some clues as to how undervalued Clarity Pharmaceuticals still is, despite the spectacular rise the last few months.

"If their data continues to hold, this is still early days, and it remains a fraction of the value of recent acquisitions in the space with early stage data."

Just last week US$100 billion giant Bristol-Myers Squibb Co (NYSE: BMY) acquired RayzeBio Inc (NASDAQ: RYZB) for US$4.1 billion, on the back of early data for its gastroenteropancreatic neuroendocrine tumour therapy and the start of a phase III trial.

"And Novartis AG (SWX: NOVN) paid US$2 billion for Endocyte in late 2018 with only Phase II data," said Frazis.

"This has proved a big winner, with first year revenues for their first product Pluvicto forecast at over US$1 billion."

This week Eli Lilly And Co (NYSE: LLY) completed its acquisition of Point Biopharma Global Inc (NASDAQ: PNT) for US$1.4 billion with only phase II data.

This is why Frazis believes that the Clarity share price remains a bargain despite the massive appreciation this year.

"In a space where companies with promising data are being acquired for billions of dollars, and Clarity's early indications look best-in-class, the company's post-runup US$340 million valuation looks cheap."

'Double or even triple industry revenues'

Prostate cancer will be "a large market", according to Frazis.

"The trend is towards increased monitoring and — where possible — fewer surgeries and hormone therapy, which involves the unwelcome side effects of incontinence, impotence, low testosterone and depression."

Currently the biotechs are treating "heavily pretreated patients", but in the longer run their solutions could be applied more proactively.

"The hope is that these targeted treatments, with their milder side effects, will move further up the treatment timeline, which could double or even triple industry revenues," said Frazis.

"This will take time, given the high hurdle for changing standard-of-care, but is looking more likely than ever today."

In the short term, both incidence and diagnosis is increasing for prostate cancer, which will keep feeding Clarity's valuation.

While the biotech stock is sparsely covered, at least Jefferies and Wilsons analysts agree with Frazis. Both teams rate Clarity Pharmaceuticals as a strong buy, as shown in CMC Invest.

Should you invest $1,000 in Clarity Pharmaceuticals right now?

Before you buy Clarity Pharmaceuticals shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Clarity Pharmaceuticals wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Bristol Myers Squibb and Point Biopharma Global. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »